Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neisseria meningitidis group C capsular polysaccharide diphtheria toxoid conjugate antigen
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Neisseria meningitidis group C capsular polysaccharide diphtheria toxoid conjugate antigen is a component of several licensed vaccines designed to prevent invasive disease caused by *Neisseria meningitidis* serogroup C. The vaccine consists of purified capsular polysaccharide from *Neisseria meningitidis* serogroup C covalently linked (conjugated) to a carrier protein, typically diphtheria toxoid or its non-toxic mutant CRM197. This conjugation enhances the immune response, especially in infants and young children, by inducing T-cell dependent immunity and immunological memory. These vaccines are indicated for active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups including C (and often A, Y, W-135 in combination products). They are used globally as part of routine immunization schedules and outbreak control measures[3][6][8].
- Brand names
- MenactraMenveo
- Other names
- Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigenMeningococcal group C conjugate vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on Neisseria meningitidis group C capsular polysaccharide diphtheria toxoid conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neisseria meningitidis group C capsular polysaccharide diphtheria toxoid conjugate antigen.